BioCentury | Apr 23, 2020
Finance

Nitrome emerges with $38M series A, platform for age-related diseases

Nitrome debuted Tuesday with a $38 million series A round, a platform targeting a newly identified class of enzymes dubbed nitrases and a lead program to treat Parkinson’s disease. Sofinnova Partners and AbbVie Ventures co-led...
BioCentury | Apr 15, 2013
Company News

NitroMed management update

NitroMed Inc. , Boston, Mass. Business; Drug delivery Promoted: L. Gordon Letts, Ph.D., to SVP and CSO; formerly VP of research WIR Staff...
BioCentury | May 18, 2009
Company News

Archemix management update

...Hematology, Cardiovascular, Cancer Hired: Kenneth Bate as president and CEO, formerly president and CEO at NitroMed Inc....
BioCentury | May 4, 2009
Company News

NicOx, Deerfield Management deal

...Nitromed Inc. unit unlicensed IP covering nitric oxide (NO)-donating compounds for € 2 million ($2.6 million). NitroMed...
...receive an additional € 4 million ($5.3 million) upon NicOx fulfilling certain future business criteria. NitroMed...
...which is marketed in the U.S. to treat heart failure in black patients. Deerfield acquired NitroMed...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

...Cytokinetics Inc.'s cardiac myosin activator CK-1827452 has completed Phase IIa testing to treat heart failure. NitroMed Inc.'s...
BioCentury | Apr 27, 2009
Finance

Avastin's tender mercies

...said portfolio manager Andy Smith. "By the time Genentech, CV Therapeutics, Tepnel Life Sciences and NitroMed...
...was acquired by Gen-Probe Inc. (NASDAQ:GPRO), CV Therapeutics Inc. was acquired by Gilead (NASDAQ:GILD), and NitroMed Inc....
BioCentury | Feb 2, 2009
Finance

Ebb & Flow

...Two separate takeouts involving NitroMed (NASDAQ:NTMD) and Exact Sciences (NASDAQ:EXAS) were upset last week, and a...
...have their own ideas about what to do with the assets. Deerfield Management finally snatched NitroMed...
...a tie-up between the two cancer companies. Deer ponies up Deerfield, which owns 12% of NitroMed...
BioCentury | Feb 2, 2009
Company News

Archemix, NitroMed, Deerfield Management, JHP Pharmaceuticals LLC deal

...in cash, valuing the biotech at $36.9 million. The price is a 25% premium to NitroMed's...
...of $0.64 on Jan. 26, before the deal was announced, and a 167% premium to NitroMed's...
...failure in black patients. Cowen and Co. LLC advised NitroMed. Archemix Corp. , Cambridge, Mass. NitroMed Inc....
BioCentury | Jan 28, 2009
Company News

NitroMed agrees to new Deerfield offer

...be acquired by Deerfield Management for $0.80 per share in cash. The price would value NitroMed...
...at $36.9 million based on 46.1 million shares outstanding and is a 25% premium to NitroMed's...
...of $1.5 million and $900,000 to Archemix and JHP, respectively. Cowen advised NitroMed. On Tuesday, NitroMed...
BioCentury | Jan 19, 2009
Company News

NitroMed, Deerfield Management deal

...to acquire NitroMed from $0.50 to $0.65 per share in cash. Subsequently, on Jan. 14, NitroMed...
...that Deerfield estimates will be at least $0.75 per share. A $0.75 offer would value NitroMed...
...$34.6 million based on 46.1 million shares outstanding and would be a 150% premium to NitroMed's...
Items per page:
1 - 10 of 198
BioCentury | Apr 23, 2020
Finance

Nitrome emerges with $38M series A, platform for age-related diseases

Nitrome debuted Tuesday with a $38 million series A round, a platform targeting a newly identified class of enzymes dubbed nitrases and a lead program to treat Parkinson’s disease. Sofinnova Partners and AbbVie Ventures co-led...
BioCentury | Apr 15, 2013
Company News

NitroMed management update

NitroMed Inc. , Boston, Mass. Business; Drug delivery Promoted: L. Gordon Letts, Ph.D., to SVP and CSO; formerly VP of research WIR Staff...
BioCentury | May 18, 2009
Company News

Archemix management update

...Hematology, Cardiovascular, Cancer Hired: Kenneth Bate as president and CEO, formerly president and CEO at NitroMed Inc....
BioCentury | May 4, 2009
Company News

NicOx, Deerfield Management deal

...Nitromed Inc. unit unlicensed IP covering nitric oxide (NO)-donating compounds for € 2 million ($2.6 million). NitroMed...
...receive an additional € 4 million ($5.3 million) upon NicOx fulfilling certain future business criteria. NitroMed...
...which is marketed in the U.S. to treat heart failure in black patients. Deerfield acquired NitroMed...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

...Cytokinetics Inc.'s cardiac myosin activator CK-1827452 has completed Phase IIa testing to treat heart failure. NitroMed Inc.'s...
BioCentury | Apr 27, 2009
Finance

Avastin's tender mercies

...said portfolio manager Andy Smith. "By the time Genentech, CV Therapeutics, Tepnel Life Sciences and NitroMed...
...was acquired by Gen-Probe Inc. (NASDAQ:GPRO), CV Therapeutics Inc. was acquired by Gilead (NASDAQ:GILD), and NitroMed Inc....
BioCentury | Feb 2, 2009
Finance

Ebb & Flow

...Two separate takeouts involving NitroMed (NASDAQ:NTMD) and Exact Sciences (NASDAQ:EXAS) were upset last week, and a...
...have their own ideas about what to do with the assets. Deerfield Management finally snatched NitroMed...
...a tie-up between the two cancer companies. Deer ponies up Deerfield, which owns 12% of NitroMed...
BioCentury | Feb 2, 2009
Company News

Archemix, NitroMed, Deerfield Management, JHP Pharmaceuticals LLC deal

...in cash, valuing the biotech at $36.9 million. The price is a 25% premium to NitroMed's...
...of $0.64 on Jan. 26, before the deal was announced, and a 167% premium to NitroMed's...
...failure in black patients. Cowen and Co. LLC advised NitroMed. Archemix Corp. , Cambridge, Mass. NitroMed Inc....
BioCentury | Jan 28, 2009
Company News

NitroMed agrees to new Deerfield offer

...be acquired by Deerfield Management for $0.80 per share in cash. The price would value NitroMed...
...at $36.9 million based on 46.1 million shares outstanding and is a 25% premium to NitroMed's...
...of $1.5 million and $900,000 to Archemix and JHP, respectively. Cowen advised NitroMed. On Tuesday, NitroMed...
BioCentury | Jan 19, 2009
Company News

NitroMed, Deerfield Management deal

...to acquire NitroMed from $0.50 to $0.65 per share in cash. Subsequently, on Jan. 14, NitroMed...
...that Deerfield estimates will be at least $0.75 per share. A $0.75 offer would value NitroMed...
...$34.6 million based on 46.1 million shares outstanding and would be a 150% premium to NitroMed's...
Items per page:
1 - 10 of 198